Innoviva, Inc.
General ticker "INVA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Innoviva, Inc. follows the US Stock Market performance with the rate: 21.6%.
Estimated limits based on current volatility of 1.6%: low 21.68$, high 22.38$
Factors to consider:
- Total employees count: 127 as of 2024
- Top business risk factors: Market competition, Dependency on GSK, Cybersecurity threats, Regulatory and compliance, Product development risks
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [17.79$, 25.20$]
- 2026-12-31 to 2027-12-31 estimated range: [19.74$, 27.63$]
Financial Metrics affecting the INVA estimates:
- Positive: with PPE of 4.9 at the end of fiscal year the price was neutral
- Positive: Operating cash flow per share per price, % of 14.70 > 12.95
- Positive: Operating profit margin, % of 39.81 > 18.38
- Negative: 0.73 < Interest expense per share per price, % of 1.25
- Negative: negative Industry operating income (median)
- Positive: Shareholder equity ratio, % of 71.73 > 64.15
- Positive: Inventory ratio change, % of -0.51 <= 0
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
Short-term INVA quotes
Long-term INVA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $310.46MM | $358.71MM | $411.33MM |
| Operating Expenses | $196.58MM | $191.84MM | $247.58MM |
| Operating Income | $113.89MM | $166.87MM | $163.75MM |
| Non-Operating Income | $80.21MM | $-129.48MM | $163.12MM |
| Interest Expense | $19.16MM | $22.21MM | $16.70MM |
| R&D Expense | $33.92MM | $13.65MM | $30.60MM |
| Income(Loss) | $194.10MM | $37.39MM | $326.86MM |
| Taxes | $14.38MM | $14.00MM | $55.70MM |
| Profit(Loss)* | $179.72MM | $23.39MM | $271.17MM |
| Stockholders Equity | $674.96MM | $691.16MM | $1,172.84MM |
| Inventory | $40.74MM | $33.73MM | $39.17MM |
| Assets | $1,243.51MM | $1,301.06MM | $1,635.16MM |
| Operating Cash Flow | $141.06MM | $188.69MM | $196.93MM |
| Capital expenditure | $0.41MM | $0.27MM | $1.13MM |
| Investing Cash Flow | $-66.76MM | $-63.79MM | $40.50MM |
| Financing Cash Flow | $-171.84MM | $-13.45MM | $8.55MM |
| Earnings Per Share** | $2.75 | $0.37 | $4.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.